Pfizer to Acquire Cancer Drug Maker Medivation in $14 Billion Deal

Pfizer to Acquire Cancer Drug Maker Medivation in $14 Billion Deal


The pharmaceutical giant announced Monday it would acquire cancer drug-maker Medivation Inc. for about $14 billion, or $81.50 per share in cash. Medivation is known for its prostate cancer treatment, which has been used to treat 64,000 men in the U.S., generating $2.2 billion in worldwide net sales over the past four quarters.



from Biotech News